Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
概览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 425
- 试验地点
- 1
- 主要终点
- Progression free survival
概览
简要总结
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.
Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.
The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- — 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of lung cancer
- •Presence of precancerous lung lesions
- •Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment
- •Control group: individuals without known lung disease
- •Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
- •Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected
排除标准
- •Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent)
- •Acute infection at the time of inclusion
- •Refusal or inability to provide informed consent (or assent, when applicable)
- •Chronic inflammatory lung disease currently treated with immunosuppressive therapy
研究组 & 干预措施
Patients with precancerous lung lesions
Patients with precancerous lung lesions under clinical monitoring
干预措施: Peripheral Blood Collection for Immune Profiling (Other)
Lung cancer
Patients with a diagnosis of lung cancer (all stages)
干预措施: Peripheral Blood Collection for Immune Profiling (Other)
Sarcoidosis and COPD
Patients with chronic inflammatory lung diseases
干预措施: Peripheral Blood Collection for Immune Profiling (Other)
Control group
Control group of volunteers without known lung disease
干预措施: Peripheral Blood Collection for Immune Profiling (Other)
chronic granulomatous disease
Children and adolescents weighing ≥10 kg with chronic granulomatous disease
干预措施: Peripheral Blood Collection for Immune Profiling (Other)
Adults undergoing orthopedic surgery following hip or femur fracture
Bone Marrow of Adults undergoing orthopedic surgery following hip or femur fracture
干预措施: Peripheral Blood Collection for Immune Profiling (Other)
结局指标
主要结局
Progression free survival
时间窗: Throughout the entire study, approximately during 7 years
median Progression free survival
次要结局
未报告次要终点